Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

Madrigal Pharmaceuticals MDGL announced that the European Commission (EC) has granted a conditional marketing authorization ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...

Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...

Madrigal Pharmaceuticals, Inc. announced the appointment of Jacqualyn Fouse, Ph.D. to its Board of Directors, replacing Fred Craves, Ph.D., who will retire in July 2025.

Conshohocken, Pennsylvania Thursday, August 21, 2025, 14:00 Hrs [IST] ...

The FDA clearance sets Novo’s medicine up for a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Bill Sibold, Madrigal Pharmaceuticals CEO, joins 'Fast Money' to discuss Q2 earnings results, the weight loss space and their GLP-1 strategy.

Madrigal Pharmaceuticals has secured conditional marketing authorization for Rezdiffra, its treatment for a serious liver condition, from regulators in Europe. The biopharmaceutical company said ...

Madrigal Pharmaceuticals (NASDAQ: MDGL), a mid-cap company, might have as decent a shot at becoming as prominent in the field as most of its similarly sized peers.

About Madrigal Pharmaceuticals Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease ...

Madrigal Pharmaceuticals currently boasts a market cap of $6.22bn. Analysts have shared peak revenue expectations from ~$2.5bn by 2027, to $3.5bn, and many carry share price targets of >$375 per ...